Feb 20, 2026Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis UpdateEvidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.
Jan 26, 2026Non-Alcoholic Fatty Liver (MASLD): Silymarin, NAC, Berberine — Evidence ReviewMASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) affects an estimated 25% of adults globally. Caloric deficit and exercise remain primary. Silymarin (milk thistle), NAC, and berberine have credible supporting evidence with consistent improvements in liver enzyme markers.